A Study to Evaluate INCA033989 Administered in Participants With

Updated 06/21/2024

Status Recruiting

Clinical Trial Summary

This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered in participants with myeloproliferative neoplasms.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06034002
Study type	Interventional
Source	Incyte Corporation
Contact	Incyte Corporation Call Center (US)
Phone	1.855.463.3463
Email	medinfo@incyte.com
Status	Recruiting
Phase	Phase 1
Start date	December 4, 2023
Completion date	October 29, 2028

See also
	Status	Clinical Trial	Phase
	Terminated	`NCT04866056` - Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.	Phase 1/Phase 2
	Recruiting	`NCT05936359` - A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	Phase 1
	Completed	`NCT02084563` - Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms	Phase 2
	Recruiting	`NCT04339400` - A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms	Phase 1
	Completed	`NCT02125318` - A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders	Phase 2
	Not yet recruiting	`NCT06291987` - Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation	Phase 1
	Recruiting	`NCT03314974` - Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders	Phase 2
	Completed	`NCT03075826` - A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms	Phase 2
	Recruiting	`NCT02823210` - Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Disorders
	Not yet recruiting	`NCT06313593` - A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms	Phase 1
	Active, not recruiting	`NCT05444530` - A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms	Phase 1
	Active, not recruiting	`NCT03912064` - A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT	Phase 1
	Terminated	`NCT02393248` - Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)	Phase 1/Phase 2
	Completed	`NCT02076191` - Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML	Phase 1/Phase 2
	Active, not recruiting	`NCT04761770` - Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders	Phase 2
	Completed	`NCT00949364` - Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage	Phase 2
	Completed	`NCT00053196` - Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer	Phase 2
	Terminated	`NCT01668173` - HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET	Phase 2
	Active, not recruiting	`NCT03618485` - Registry of Patients With MPNs in Taiwan